Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models

被引:177
作者
Pchejetski, D
Golzio, M
Bonhoure, E
Calvet, C
Doumerc, N
Garcia, V
Mazerolles, C
Rischmann, P
Teissié, J
Malavaud, B
Cuvillier, O
机构
[1] INSERM, U466, F-31432 Toulouse, France
[2] CNRS, Inst Pharmacol & Biol Struct, UMR 5089, Toulouse, France
[3] Univ Toulouse 3, Fac Med, Hop Rangueil, Serv Urol & Transplantat Renale, F-31062 Toulouse, France
[4] Univ Toulouse 3, Fac Med, Hop Rangueil, Serv Anat & Cytol Pathol, F-31062 Toulouse, France
关键词
D O I
10.1158/0008-5472.CAN-05-2702
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Systemic chemotherapy was considered of modest efficacy in prostate cancer until the recent introduction of taxanes. We took advantage of the known differential effect of camptothecin and docetaxel on human PC-3 and LNCaP prostate cancer cells to determine their effect. on sphingosine kinase-1 (SphK1) activity and subsequent ceramide/sphingosine 1-phosphate (SIP) balance in relation with cell survival. In vitro, docetaxel and camptothecin induced strong inhibition of SphK1 and elevation of the ceramide/S1P ratio only in cell lines sensitive to these drugs. SphK1 overexpression in both cell lines impaired the efficacy of chemotherapy by decreasing the ceramide/S1P ratio. Alternatively, silencing SphK1 by RNA interference or pharmacologic inhibition induced apoptosis coupled with ceramide elevation and loss of S1P. The differential effect of both chemotherapeutics was confirmed in an orthotopic PC-3/ green fluorescent protein model established in nude mice. Docetaxel induced a stronger SphK1 inhibition and ceramide/ SIP ratio elevation than camptothecin. This was accompanied by a smaller tumor volume and the reduced occurrence and number of metastases. SphK1-overexpressing PC-3 cells implanted in animals developed remarkably larger tumors and resistance to docetaxel treatment. These results provide the first in vivo demonstration of SphK1 as a sensor of chemotherapy.
引用
收藏
页码:11667 / 11675
页数:9
相关论文
共 50 条
[1]   Ceramide accumulation is independent of camptothecin-induced apoptosis in prostate cancer LNCaP cells [J].
Akao, Y ;
Kusakabe, S ;
Banno, Y ;
Kito, M ;
Nakagawa, Y ;
Tamiya-Koizumi, K ;
Hattori, M ;
Sawada, M ;
Hirabayasi, Y ;
Ohishi, N ;
Nozawa, Y .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 294 (02) :363-370
[2]  
Arah IN, 1998, ANTICANCER RES, V18, P1845
[3]  
Asakuma J, 2003, CANCER RES, V63, P1365
[4]   Novel therapeutic strategies for androgen-independent prostate cancer: An update [J].
Assikis, VJ ;
Simons, JW .
SEMINARS IN ONCOLOGY, 2004, 31 (02) :26-32
[5]   Akt activation induced by lysophosphatidic acid and sphingosine-1-phosphate requires both mitogen-activated protein kinase kinase and p38 mitogen-activated protein kinase and is cell-line specific [J].
Baudhuin, LM ;
Cristina, KL ;
Lu, J ;
Xu, Y .
MOLECULAR PHARMACOLOGY, 2002, 62 (03) :660-671
[6]   Sphingosine kinase activity counteracts ceramide-mediated cell death in human melanoma cells:: role of Bcl-2 expression [J].
Bektas, M ;
Jolly, PS ;
Müller, C ;
Eberle, R ;
Spiegel, S ;
Geilen, CC .
ONCOGENE, 2005, 24 (01) :178-187
[7]   Clinical trials in metastatic prostate cancer - Has there been real progress in the past decade? [J].
Bhandari, MS ;
Petrylak, DP ;
Hussain, M .
EUROPEAN JOURNAL OF CANCER, 2005, 41 (06) :941-953
[8]  
BONHOURE E, 2005, IN PRESS LEUKEMIA
[9]  
BORNER MM, 1995, CANCER RES, V55, P2122
[10]   Lack of ceramide generation in TF-1 human myeloid leukemic cells resistant to ionizing radiation [J].
Bruno, AP ;
Laurent, G ;
Averbeck, D ;
Demur, C ;
Bonnet, J ;
Bettaïeb, A ;
Levade, T ;
Jaffrézou, JP .
CELL DEATH AND DIFFERENTIATION, 1998, 5 (02) :172-182